Advances in Hematology最新文献

{"title":"Treatment Patterns and Outcomes of Patients With Myelodysplastic Syndrome (MDS) by IPSS-R Scores at Academic Cancer Centers.","authors":"Connor Willis, Andre Hejazi, Vonetta L Williams, Craig Comperatore, Srinivas Tantravahi, Najla Al Ali, Jeffrey Gilreath, Tibor Kovacsovics, Trang Au, Malinda Tan, Madeline Brendle, Rami Komrokji, Minkyoung Yoo, Mushtaq Ashraf, Aamir Khakwani, Şerban R Iorga, Islam Sadek, David A Sallman, David Stenehjem","doi":"10.1155/ah/9924808","DOIUrl":"10.1155/ah/9924808","url":null,"abstract":"<p><p>This study describes treatment patterns and clinical and economic outcomes of patients with myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) risk scores. A retrospective cohort study was conducted including adults diagnosed with MDS between 2010 and 2020 within two academic institutions. A total of 369 patients were included. Hypomethylating agents (HMAs) were used as first-line therapy in 81% (<i>n</i> = 230) and 51% (<i>n</i> = 44) of higher-risk (HR) and lower-risk (LR) patients, respectively. Second-line therapy was received by 24% of patients. Complete response was achieved by 11% of HR patients (median duration: 24 months). Median PFS and OS were 9.5 and 18.8 months in the HR cohort and 18.8 and 25.6 months in the LR cohort. Mean MDS-related healthcare charges per patient per month were > 2-fold higher among HR patients compared to LR (<i>p</i> < 0.001). An unmet need exists for first and subsequent lines of therapy.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"9924808"},"PeriodicalIF":0.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12629909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145585840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Strategy for Assessing Bone Marrow Plasma Cell Percentage: Development and Internal Validation of a Surrogate Calculation Approach.","authors":"Ethan James Gantana, Zivanai Cuthbert Chapanduka","doi":"10.1155/ah/1191575","DOIUrl":"10.1155/ah/1191575","url":null,"abstract":"<p><strong>Introduction: </strong>The differentiation and diagnosis of plasma cell (PC) neoplasms (PCNs) such as multiple myeloma (MM) rely on the quantification of clonal PCs in the bone marrow (BM). For monitoring, the International Myeloma Working Group (IMWG) defines stringent response criteria based on the percentage of BM PC. However, BM biopsies are invasive and painful, and often with sampling variability. This study investigates whether routine biomarkers can predict BM trephine (BMT) PC% using multivariate regression.</p><p><strong>Methods: </strong>A cross-sectional study was conducted at Tygerberg Hospital, South Africa. Data were extracted from the National Health Laboratory Service (NHLS) database. The final dataset included 112 newly diagnosed MM patients with complete biomarker data for training of the partial least squares regression (PLS-R) model. Variables analyzed included SFLC ratio, paraprotein, Hb, calcium, creatinine, and albumin. Statistical methods included correlation analysis, regression modeling, and internal validation.</p><p><strong>Results: </strong>The cohort had a median age of 61 years and a male-to-female ratio of 1:1.5. PLS-R analysis identified significant predictors of BMT PC%, including SFLC ratio, paraprotein, Hb, and serum albumin. The final model equation showed moderate predictive power (<i>Q</i> ² = 0.410, <i>R</i> ² <i>Y</i> = 0.432). Spearman correlation analysis showed a moderate positive relationship (<i>p</i> = 0.585) between predicted and actual BMT PC%. Linear regression analysis also confirmed that BMA PC% (<i>R</i> ² = 0.489) was a stronger predictor of BMT PC% than flow cytometry PC% (<i>R</i> ² = 0.184).</p><p><strong>Conclusion: </strong>This study provides proof of concept for the use of biochemical markers to predict BMT PC% and offers a less invasive alternative for PC quantification in PCN. Standardization of sampling and measurement of biomarkers is essential for the refinement of these predictive models. Future multicenter studies should include prospective data collection to improve model accuracy and clinical applicability.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"1191575"},"PeriodicalIF":0.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12616256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145538596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Adverse Blood Donation Reactions Among Whole Blood Donors at a Tertiary Hospital Setting: A One-Center Observational Mixed-Methods Study.","authors":"Redeemer Nana Fabea Addae, Patience Sobre, Inusah Abdul Mumin, Addo Samuel Siaw, Nichodemus Parker Quansah, Abigail Asmah-Brown, Prosper Junior Awittor, Joseph Boachie, Patrick Adu","doi":"10.1155/ah/3668746","DOIUrl":"10.1155/ah/3668746","url":null,"abstract":"<p><strong>Background: </strong>Although blood donation saves lives, it may be associated with adverse reactions. These reactions may be immediate or delayed and may be a factor in donor nonreturn. However, there is limited knowledge about blood donation-related adverse reactions and risk factors specific to the Ghanaian context.</p><p><strong>Aim: </strong>To determine the prevalence of adverse blood donation reactions and associated risk factors among successful blood donors at a tertiary hospital setting.</p><p><strong>Materials and methods: </strong>This mixed-methods research (May-June 2024) used observational techniques and semistructured questionnaires to investigate adverse reactions during and after blood donation. The study recruited 279 participants (241 mobile session donors and 38 in-house donations) in a tertiary setting blood collection center. Bivariate logistic regression analysis was performed to evaluate the influence of some donor demographics on adverse reactions.</p><p><strong>Results: </strong>Overall, the prevalence of immediate adverse reaction was 44.4%; 51.4%, 36.5%, and 12.1% were local, vasovagal, and allergies, respectively. Blood donors who experienced adverse events had a statistically significantly lower median age (<i>p</i> = 0.007), lower systolic blood pressure (<i>p</i> = 0.004), lower diastolic pressure (<i>p</i> = 0.007), and lower weight (<i>p</i> = 0.030). Also, 22.1% of adverse donor reactions persisted 24 h postdonation; 38.7%, 58.1%, and 3.2% were local, vasovagal, and allergies, respectively. Bivariate logistics regression analysis showed that 16-19 years (aOR, 2.572, p = 0.477), males (aOR, 1.492, p = 0.125), students (aOR, 2.421, p = 0.325), the mobile session (aOR, 1.063, p = 0.928), and first-time donors (aOR, 1.139, p = 0.690) were associated with nonstatistically significantly increased risk of immediate adverse donor reactions.</p><p><strong>Conclusion: </strong>There is an urgent need to build staff competencies and operationalize standard operating protocols to enable staff to identify and handle adverse blood donation events quickly. Further studies are needed to understand the factors responsible for the high prevalence of adverse donor reactions to inform improvements in blood donor care.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"3668746"},"PeriodicalIF":0.0,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12571990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145429988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Issue of Screening for Transfusion-Transmitted Infections in Sub-Saharan Africa Presents Several Challenges: A Review.","authors":"F Y Djientcheu Deugoue, M Azabji-Kenfack, C Tayou Tagny, M A Kouamou Tchiekou, S A Menteng Tchuente, Veronique Deneys","doi":"10.1155/ah/1373786","DOIUrl":"10.1155/ah/1373786","url":null,"abstract":"<p><p>Blood transfusion is a vital medical procedure with the potential to save lives; however, it can have serious consequences if not carried out under rigorous principles. Sub-Saharan Africa (SSA) faces considerable challenges in ensuring the security of the transfusion process, particularly in the context of transfusion-transmissible infections (TTIs). These difficulties are principally associated with the elevated prevalence of TTI in the region, including viral (e.g., hepatitis B, HIV and hepatitis C), bacterial (e.g., syphilis), and parasitic (e.g., malaria) diseases, among others. Also, the family replacement donation system, economic and technological limitations and an insufficient donor pool constitute substantial obstacles. Various solutions are currently being recommended, implemented, or applied on a variable scale, depending on the specific country and subregion, to address the challenges above. For instance, it would be judicious to implement measures to prevent infections, such as rigorous donor selection, quality testing for the primary TTI, and pathogen inactivation. This would necessitate deploying innovative and adapted communication strategies to establish a sufficient pool of regular, unpaid voluntary donors and high-quality screening. Therefore, robust and coherent national or regional blood transfusion policies should support the previously outlined measures. These policies should include rigorous quality control and haemovigilance systems and reflect local epidemiological and economic realities.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"1373786"},"PeriodicalIF":0.0,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12562600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145399787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Endothelial-Independent Effect of Desmopressin, In Vitro, on Platelet Function.","authors":"Michael V Forner, Etheresia Pretorius, Chantelle Venter, Sean Chetty","doi":"10.1155/ah/9928082","DOIUrl":"10.1155/ah/9928082","url":null,"abstract":"<p><p>Platelets form the nidus around which the primary hemostatic cascade is amplified and propagated. Desmopressin (DDAVP) has been shown to enhance platelet function through interaction with the endothelium. Evidence suggests that an alternative mechanism of action may exist. We aimed to determine the effect of DDAVP on platelet function and microclotting of plasma proteins in samples from healthy volunteers. We analyzed blood samples in 20 healthy volunteers with no coagulation abnormalities. Control and test samples were drawn from each participant. DDAVP was added in vitro to test samples. All samples were subjected to PFA-200, viscoelastic (VET) and fluorescence microscopy testing. DDAVP increased TEG MA and decreased K-time in experimental samples. There was no difference between the means in the clotting times in either of the PFA-200 groups. Fluorescence microscopy examining platelet activation and microclot formation showed significant increases in both parameters in the test samples. The results contrast current literature, which suggests that DDAVP has no effect on platelet function independent of the endothelium. This is the first study demonstrating an in vitro effect of DDAVP on platelets examined by VET and microscopy. We conclude that a relationship exists between DDAVP exposure, in vitro, platelet activation and microclot formation.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"9928082"},"PeriodicalIF":0.0,"publicationDate":"2025-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12539662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145375847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Soluble B-cell Maturation Antigen in Multiple Myeloma and Correlation With Response to Therapy.","authors":"Souvik Saha, Prankrishna Kakati, Kulwant Singh, Manish Kumar Singh, Khaliqur Rahman, Sanjeev Yadav, Dinesh Chandra, Ruchi Gupta, Rajesh Kashyap","doi":"10.1155/ah/6664621","DOIUrl":"10.1155/ah/6664621","url":null,"abstract":"<p><strong>Aim: </strong>B-cell maturation antigen (BCMA) is a nontyrosine kinase receptor expressed during plasma cell differentiation. Binding of ligands such as APRIL and BAFF to BCMA on malignant plasma cells leads to proliferation of tumor cells and plays an important role in the pathogenesis of multiple myeloma. Recent studies have explored the role of serum-soluble BCMA (sBCMA) in assessing tumor load as well as monitoring of response. In this study, we aimed to detect serum sBCMA levels in newly diagnosed multiple myeloma patients as well as monitor the levels at follow-up to correlate with response to therapy.</p><p><strong>Methods: </strong>This was a prospective, longitudinal study conducted between March 2023 and July 2024. We documented the routine disease characteristics along with sBCMA levels at baseline and followed up sBCMA levels as a marker of therapy response.</p><p><strong>Results: </strong>Baseline sBCMA levels were significantly higher in patients presenting with anemia and hypercalcemia and in patients having high-risk cytogenetics. There was a trend toward correlation of sBCMA levels with bone marrow plasma cell percentage, β2-microglobulin, and thrombocytopenia. We also found significant association of the sBCMA level with both ISS and R-ISS staging. Furthermore, we assessed the response to therapy in terms of IMWG response criteria and sBCMA-based response. The response according to conventional response criteria correlated significantly with sBCMA-based response. We also found a significant association of decline in sBCMA levels to that of M band on response to therapy. There are certain advantages of using sBCMA as a response monitoring tool, such as in patients with renal impairment and in nonsecretory myeloma.</p><p><strong>Conclusion: </strong>Our study provides an important insight into the relation of sBCMA to disease characteristics and the kinetics of decline in sBCMA on response to therapy.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"6664621"},"PeriodicalIF":0.0,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12539665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145375792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficiency and Safety of Brentuximab Vedotine as a Salvage Treatment Before Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: Retrospective Study.","authors":"Kateryna Filonenko, Yana Stepanishyna, Nazar Shokun, Arina Martynchyk, Yevhen Kushchevyi, Iryna Kriachok, Jan Maciej Zaucha","doi":"10.1155/ah/3573471","DOIUrl":"10.1155/ah/3573471","url":null,"abstract":"<p><strong>Background: </strong>There is no strong evidence supporting brentuximab vedotine (BV) efficacy as a salvage regimen for relapsed/refractory Hodgkin's lymphoma (R/R HL) patients before autologous hematopoietic cell transplantation (auto-HCT).</p><p><strong>Methods: </strong>We performed multicenter retrospective analysis of efficiency of treatment with the BV monotherapy as salvage regimen versus standard salvage chemotherapy (sCT) in 44 patients with R/R HL from a high-risk group.</p><p><strong>Results: </strong>Twenty-six patients (59.1%) had primary refractory disease. Nineteen patients (43.2%) received BV salvage treatment before auto-HCT, and 12 (63.6%) achieved complete response (CR) that counts 27.3% of the whole study cohort. There was no difference in the CR rate, 2-year progression-free survival, and 2-year overall survival after BV salvage and sCT (63.2% vs. 60%, respectively, <i>p</i> = 0.35; 88.2% vs. 80.7%, <i>p</i> = 0.655; 94.1% vs. 100%, <i>p</i> = 0.735, respectively). There was no difference in neuropathy of all grades, including Grades 2-3 between groups.</p><p><strong>Conclusions: </strong>The BV as a salvage treatment showed quite high efficiency. Despite a worse clinical characteristic of the BV group, there were no significant differences in the outcomes of the auto-HCT with respect to the salvage regimen (BV versus sCT) used before auto-HCT. Our results suggest that BV before auto-HCT in patients refractory to standard 2nd line treatment equalizes their prognosis to the patient sensitive to standard CT with the same tolerance and toxicity.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"3573471"},"PeriodicalIF":0.0,"publicationDate":"2025-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12539663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145372111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Role of HOTAIR and MALAT1 Long Noncoding RNAs and Their Relations With Bone Marrow Environment in Acute Myeloid Leukemia Subtypes: Biomarkers and Treatment Response.","authors":"Hero Hamad, Goran Othman, Ranan Kardagh","doi":"10.1155/ah/3459924","DOIUrl":"10.1155/ah/3459924","url":null,"abstract":"<p><p>Long noncoding RNAs have recently emerged as major players in cancer by operating through complex structural and functional diversity in a wide range of cellular processes. Among these, certain lncRNAs, including MALAT1 and HOTAIR, have been in the limelight concerning AML for their important roles played in regulating gene expression that in turn influence the disease course of AML. This review summarizes the structure and classification of lncRNAs, mechanisms of action regarding cancer biology, and how lncRNAs such as MALAT1 and HOTAIR act as oncogenes or tumor suppressors. It also examines intricate correlations among these lncRNAs and the bone marrow microenvironment with regard to effects on AML cell proliferation, migration, and survival. In the current review, the key pathways in AML, through which MALAT1 and HOTAIR drive cellular proliferation and epigenetic processes, are discussed in detail to point out possible therapeutic targets. The interactions between MALAT1 and HOTAIR within the bone marrow microenvironment suggest the diverse involvement of lncRNAs in AML and support their applications in biomarker development and as novel avenues for targeted therapies. This review thus represents a broad overview with the intention of furthering our understanding of the lncRNA-mediated pathways in AML and their use as diagnostic and therapeutic tools.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"3459924"},"PeriodicalIF":0.0,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12530475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145328024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis (EDKA) in Hematologic Malignancy Patients: A Case Series.","authors":"Andrew Artz, Tiffany Nguyen, Raynald Samoa, Hoim Kim, Wyndie Tse, Rami Jin, Svetlana Goutnik","doi":"10.1155/ah/7244013","DOIUrl":"10.1155/ah/7244013","url":null,"abstract":"<p><p>Sodium-glucose Cotransporter 2 inhibitors (SGLT2i) are widely used and effective pharmacotherapeutic options that are first-line therapy for Type 2 diabetes mellitus (T2DM) and congestive heart failure. A major adverse effect of SGLT2i usage is diabetic ketoacidosis (DKA). SGLT2i-induced DKA commonly presents as euglycemic DKA (EDKA). The safety of empagliflozin in cancer patients is not well established. High intensity treatment of hematologic malignancy poses a unique set of risk factors for EDKA. Four cases of empagliflozin-associated EDKA in hematologic malignancy patients were identified through pharmacy adverse event reporting at a cancer research hospital. All patients were euglycemic except one patient who required CRS/ICANS treatment with dexamethasone, causing steroid-induced hyperglycemia. All four patients had weight loss due to reasons including, but not limited to, reduced oral intake, diarrhea, nausea, and pain. Infections and/or neutropenic fever were also commonalities throughout the four patients. In all patients, DKA contributed to iatrogenic ICU admissions and prolonged hospital stays. SGLT2i use in hematologic malignancy patients may increase the risk of DKA due to high risk of anorexia, weight loss, and infections, all highly associated with intensive treatment that can disrupt the availability and sensitivity to insulin. In patients receiving SGLT2i, clinicians should be aware of risk factors for DKA as well as potential euglycemic presentation to ensure close clinical and laboratory monitoring to facilitate rapid diagnosis and treatment of DKA.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"7244013"},"PeriodicalIF":0.0,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12530474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145327987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Anemia and Associated Factors Among Undergraduate Students at SIMAD University, Mogadishu, Somalia.","authors":"Fardowsa Mohamed Yusuf, Leena Babiker Mirghani, Abdirasak Sharif Ali","doi":"10.1155/ah/6398491","DOIUrl":"10.1155/ah/6398491","url":null,"abstract":"<p><strong>Background: </strong>Anemia remains a significant public health issue, affecting populations worldwide, particularly in low-income countries. Despite its widespread prevalence, no comprehensive studies have been conducted to assess the prevalence of anemia or its associated factors among university students in Somalia. This study aimed to assess the prevalence of anemia and its associated factors among undergraduate students at SIMAD University, Mogadishu, Somalia.</p><p><strong>Methodology: </strong>A cross-sectional study was conducted involving 264 participants from various faculties. Data on sociodemographic factors, medical and lifestyle factors, and hemoglobin (Hb) concentrations were collected. Statistical analysis including descriptive statistics, Pearson chi-square tests, and logistic regression was performed to determine associations between variables and anemia prevalence.</p><p><strong>Results: </strong>The mean age of participants was 20.3 ± 2.5 years, with an equal distribution of male and female students. The overall prevalence of anemia was 48.1%. Higher rates of anemia were observed among females (<i>p</i> < 0.001) and those not engaging in regular exercise (<i>p</i> = 0.001). Logistic regression showed that being male (OR = 0.409, 95% CI: 0.249-0.671) and engaging in exercise (OR = 0.299, 95% CI: 0.168-0.532) were protective against anemia. History of hospitalization showed a nonsignificant association with increased anemia risk (OR = 1.523, <i>p</i> = 0.121). A knowledge assessment revealed that 64.4% of the participants had good knowledge of anemia.</p><p><strong>Conclusion: </strong>Anemia was highly prevalent (48.1%) among undergraduate students, particularly among females and those not engaging in regular exercise. Male gender and physical activity were protective factors. Despite good knowledge levels, the burden remains significant. Targeted awareness campaigns, routine screening, and interventions promoting healthy lifestyles are essential to reduce anemia and its impact on students' health and academic performance. Further research should guide context-specific policy development.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"6398491"},"PeriodicalIF":0.0,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145278774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}